Akari CEO abruptly resigns as a special committee moves a PhII patient success into the fail column
Akari Therapeutics CEO Gur Roshwalb is out.
The biotech reported after the market closed on Tuesday that Roshwalb had resigned — effective immediately — after the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.